vs

Side-by-side financial comparison of Arcturus Therapeutics Holdings Inc. (ARCT) and NexPoint Real Estate Finance, Inc. (NREF). Click either name above to swap in a different company.

NexPoint Real Estate Finance, Inc. is the larger business by last-quarter revenue ($11.1M vs $7.2M, roughly 1.5× Arcturus Therapeutics Holdings Inc.). On growth, NexPoint Real Estate Finance, Inc. posted the faster year-over-year revenue change (-48.8% vs -68.4%).

Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA (siRNA), messenger RNA (mRNA), gene editing RNA, DNA, antisense oligonucleotides, and microRNA.

NexPoint Real Estate Finance, Inc. is a US-based commercial real estate finance firm that offers structured financing solutions for multifamily, office, industrial, and hospitality properties. It focuses on originating, managing and servicing a diversified portfolio of mortgage loans and real estate-related investments to deliver stable risk-adjusted returns to stakeholders.

ARCT vs NREF — Head-to-Head

Bigger by revenue
NREF
NREF
1.5× larger
NREF
$11.1M
$7.2M
ARCT
Growing faster (revenue YoY)
NREF
NREF
+19.6% gap
NREF
-48.8%
-68.4%
ARCT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ARCT
ARCT
NREF
NREF
Revenue
$7.2M
$11.1M
Net Profit
$24.0M
Gross Margin
Operating Margin
Net Margin
216.6%
Revenue YoY
-68.4%
-48.8%
Net Profit YoY
3.1%
58.7%
EPS (diluted)
$0.47

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARCT
ARCT
NREF
NREF
Q4 25
$7.2M
$11.1M
Q3 25
$17.2M
$12.5M
Q2 25
$28.3M
$12.1M
Q1 25
$29.4M
$11.5M
Q4 24
$22.8M
$21.7M
Q3 24
$41.7M
$12.5M
Q2 24
$49.9M
$6.7M
Q1 24
$38.0M
$-12.8M
Net Profit
ARCT
ARCT
NREF
NREF
Q4 25
$24.0M
Q3 25
$-13.4M
$50.9M
Q2 25
$-9.2M
$22.3M
Q1 25
$-14.1M
$26.0M
Q4 24
$-30.0M
$15.2M
Q3 24
$-6.9M
$23.3M
Q2 24
$-17.2M
$12.1M
Q1 24
$-26.8M
$-14.6M
Operating Margin
ARCT
ARCT
NREF
NREF
Q4 25
Q3 25
-96.3%
Q2 25
-41.0%
Q1 25
-57.3%
Q4 24
-146.7%
Q3 24
-25.8%
Q2 24
-42.4%
Q1 24
-80.0%
Net Margin
ARCT
ARCT
NREF
NREF
Q4 25
216.6%
Q3 25
-78.4%
407.0%
Q2 25
-32.4%
184.5%
Q1 25
-47.9%
225.6%
Q4 24
-131.8%
69.9%
Q3 24
-16.6%
186.4%
Q2 24
-34.5%
179.7%
Q1 24
-70.5%
114.3%
EPS (diluted)
ARCT
ARCT
NREF
NREF
Q4 25
$0.47
Q3 25
$-0.49
$1.14
Q2 25
$-0.34
$0.54
Q1 25
$-0.52
$0.70
Q4 24
$-1.10
$0.71
Q3 24
$-0.26
$0.74
Q2 24
$-0.64
$0.40
Q1 24
$-1.00
$-0.83

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARCT
ARCT
NREF
NREF
Cash + ST InvestmentsLiquidity on hand
$230.9M
$31.1M
Total DebtLower is stronger
$771.2M
Stockholders' EquityBook value
$214.0M
$388.0M
Total Assets
$271.1M
$5.3B
Debt / EquityLower = less leverage
1.99×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARCT
ARCT
NREF
NREF
Q4 25
$230.9M
$31.1M
Q3 25
$180.4M
$17.9M
Q2 25
$196.5M
$9.1M
Q1 25
$216.9M
$19.2M
Q4 24
$237.0M
$3.9M
Q3 24
$237.2M
$34.7M
Q2 24
$260.3M
$4.3M
Q1 24
$288.4M
$13.5M
Total Debt
ARCT
ARCT
NREF
NREF
Q4 25
$771.2M
Q3 25
$720.9M
Q2 25
$815.6M
Q1 25
$831.5M
Q4 24
$799.3M
Q3 24
$815.5M
Q2 24
$861.0M
Q1 24
$843.3M
Stockholders' Equity
ARCT
ARCT
NREF
NREF
Q4 25
$214.0M
$388.0M
Q3 25
$224.6M
$375.4M
Q2 25
$231.1M
$348.2M
Q1 25
$233.8M
$343.7M
Q4 24
$241.0M
$336.5M
Q3 24
$261.9M
$335.8M
Q2 24
$258.6M
$327.5M
Q1 24
$264.0M
$327.1M
Total Assets
ARCT
ARCT
NREF
NREF
Q4 25
$271.1M
$5.3B
Q3 25
$282.3M
$5.3B
Q2 25
$309.3M
$5.4B
Q1 25
$331.8M
$5.4B
Q4 24
$344.1M
$5.4B
Q3 24
$370.7M
$5.7B
Q2 24
$388.6M
$6.6B
Q1 24
$418.8M
$7.1B
Debt / Equity
ARCT
ARCT
NREF
NREF
Q4 25
1.99×
Q3 25
1.92×
Q2 25
2.34×
Q1 25
2.42×
Q4 24
2.38×
Q3 24
2.43×
Q2 24
2.63×
Q1 24
2.58×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARCT
ARCT
NREF
NREF
Operating Cash FlowLast quarter
$-74.3M
$-4.5M
Free Cash FlowOCF − Capex
$-74.5M
FCF MarginFCF / Revenue
-1035.2%
Capex IntensityCapex / Revenue
3.2%
Cash ConversionOCF / Net Profit
-0.19×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARCT
ARCT
NREF
NREF
Q4 25
$-74.3M
$-4.5M
Q3 25
$-17.2M
$8.1M
Q2 25
$-5.8M
$3.3M
Q1 25
$-35.1M
$16.0M
Q4 24
$-284.0K
$4.4M
Q3 24
$-23.8M
$14.7M
Q2 24
$-30.1M
$-7.5M
Q1 24
$-5.6M
$17.7M
Free Cash Flow
ARCT
ARCT
NREF
NREF
Q4 25
$-74.5M
Q3 25
$-17.3M
Q2 25
Q1 25
$-35.3M
Q4 24
Q3 24
$-23.8M
Q2 24
$-30.5M
Q1 24
$-5.8M
FCF Margin
ARCT
ARCT
NREF
NREF
Q4 25
-1035.2%
Q3 25
-101.1%
Q2 25
Q1 25
-120.1%
Q4 24
Q3 24
-57.2%
Q2 24
-61.1%
Q1 24
-15.3%
Capex Intensity
ARCT
ARCT
NREF
NREF
Q4 25
3.2%
Q3 25
1.1%
Q2 25
0.0%
Q1 25
0.5%
Q4 24
0.0%
Q3 24
0.2%
Q2 24
0.7%
Q1 24
0.6%
Cash Conversion
ARCT
ARCT
NREF
NREF
Q4 25
-0.19×
Q3 25
0.16×
Q2 25
0.15×
Q1 25
0.62×
Q4 24
0.29×
Q3 24
0.63×
Q2 24
-0.62×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons